Navigation Links
U of M researcher examines newly emerging deadly disease

Researchers at the University of Minnesota have identified a newly emerging illness, named staphylococcal purpura fulminans. The disease begins as a respiratory tract infection, which then is infected by Staphylococcus aureus. The infection then moves to the lungs, making superantigens (bacterial toxins that activate large numbers of T cells), often leading to death due to hypertension and shock. Purpura fulminans has been identified in five cases in the Minneapolis-St. Paul, Minn., metropolitan area during 2000-2004, as described in the April 1, 2005 issue of Clinical Infectious Diseases. This new disease has also been determined in seven additional cases nationwide. Of the 12 known cases, only two patients have survived.

Purpura fulminans is an acute illness commonly associated with meningococcemia or invasive streptococcal disease, and it is typically characterized by the depletion of clotting factors in the blood and skin lesions. Purpura fulminans refers to widespread severe purpura with extensive tissue damage and sloughing of skin. Purpura are skin lesions that may be many centimeters in diameter caused by the leakage of blood into the skin.

"It is important to alert medical professionals about the symptoms and treatments of this new deadly disease," said Patrick Schlievert, Ph.D., professor of microbiology at the University of Minnesota Medical School. "We are continuing to study and monitor cases of purpura fulminans to better understand the causes and best treatment options."

On the basis of experience, the University of Minnesota experts have identified three recommended treatments for purpura fulminans. Patients who present symptoms of purpura should receive antibiotic therapy not only against Neisseria meningitidis and streptococci, but also against methicillin-resistant S. aureus (MRSA), with the consideration that the staphylococcal disease may be more common than the two prior illnesses. Patients should also be given early admi nistration of activated protein C (i.e., drotrecogin) in an attempt to minimize purpuric skin injury and to slow the inflammatory cascade before irreparable tissue injury occurs. In addition, because toxic shock syndrome is mediated by superantigens, it is possible that intravenous immunoglobulin therapy may be indicated. Of the five patients observed in the Minneapolis-St. Paul area during the period of 2000-2004, four of the patients were previously healthy and four of the patients were women. Schlievert and colleagues hypothesize that the clinical features of purpura fulminans and toxic shock syndrome seen in these patients resulted from massive cytokine release induced by the S. aureus strains.


'"/>

Source:University of Minnesota


Related biology news :

1. NYU researchers simulate molecular biological clock
2. Vital step in cellular migration described by UCSD medical researchers
3. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
4. UCSD researchers maintain stem cells without contaminated animal feeder layers
5. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
6. New protein discovered by Hebrew University researchers
7. First real-time view of developing neurons reveals surprises, say Stanford researchers
8. Agilent Technologies releases automated literature search tool for biology researchers
9. Self-assembled nano-sized probes allow Penn researchers to see tumors through flesh and skin
10. Yale researchers identify molecule for detecting parasitic infection in humans
11. US life expectancy about to decline, researchers say
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
(Date:6/1/2016)... 1, 2016 Favorable Government Initiatives ... and Criminal Identification to Boost Global Biometrics System Market ... TechSci Research report, " Global Biometrics Market By ... and Opportunities, 2011 - 2021", the global biometrics market ... on account of growing security concerns across various end ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
Breaking Biology Technology: